Athenex Inc (NASDAQ:ATNX) CEO Johnson Yiu Nam Lau acquired 10,000 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was acquired at an average price of $14.90 per share, for a total transaction of $149,000.00. Following the completion of the purchase, the chief executive officer now owns 3,031,959 shares of the company’s stock, valued at approximately $45,176,189.10. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Athenex stock traded down $0.40 on Thursday, reaching $14.82. 357,277 shares of the stock were exchanged, compared to its average volume of 486,927. Athenex Inc has a 1-year low of $9.38 and a 1-year high of $21.11. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.62 and a quick ratio of 2.33. The stock’s fifty day simple moving average is $18.44. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -10.29 and a beta of -0.30.
Athenex (NASDAQ:ATNX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.44). Athenex had a negative net margin of 161.17% and a negative return on equity of 85.39%. The business had revenue of $22.20 million for the quarter, compared to analyst estimates of $18.15 million. On average, sell-side analysts anticipate that Athenex Inc will post -1.92 earnings per share for the current fiscal year.
A number of research firms have commented on ATNX. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price objective (up from $29.00) on shares of Athenex in a research note on Tuesday, June 25th. Zacks Investment Research lowered shares of Athenex from a “hold” rating to a “sell” rating in a research note on Tuesday, July 9th. Oppenheimer began coverage on shares of Athenex in a research note on Thursday, May 2nd. They issued an “outperform” rating and a $20.00 price objective on the stock. BidaskClub lowered shares of Athenex from a “buy” rating to a “hold” rating in a research note on Friday, July 19th. Finally, SunTrust Banks boosted their price target on shares of Athenex to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $23.83.
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
Recommended Story: How does inflation affect different investments?
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.